StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Constant Currency Growth in Rest of World (% cc) by Quarter

Constant Currency Growth in Rest of World (% cc) (%)

QuarterlyAnnual

Novartis Constant Currency Growth in Rest of World (% cc): 46.0% in Q3 2026, down 27.0 pts from a year earlier. That is the lowest of the 10 quarters on record here.

Latest, Q3 2026
46.0%
Period ended Sep 30, 2026
Change on a year earlier
-27.0 pts
73.0% in Q3 2025
History
10 quarters
Since Q2 2024
Sources
10
Documents cited below

Where the Q3 2026 figure comes from

“|| Scemblix | Oncology | Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP); Ph+ CML in CP with the T315I mutation | 414 | 78 | 179 | 43 | 46 | 593 | 66 | 67”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedConstant Currency Growth in Rest of World (% cc) (%)Year on yearSource
Q3 2026Sep 30, 202646.0%-27.0 ptsNovartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202682.0%+6.0 ptsNovartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202668.0%-9.0 ptsNovartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202583.0%+3.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202573.0%-42.0 ptsNovartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 202576.0%-36.0 ptsNovartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 202577.0%–Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 202480.0%–Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024115.0%–Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024112.0%–Novartis Form 6-K (0001370368-24-000019) ↗

Cite this data

StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), quarterly Q2 2024–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-scemblix-row-yoy-cc-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.